- Home
- UFCS vs AUTL Comparison
UFCS vs AUTL Comparison
Compare UFCS & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFCS
- AUTL
- Stock Information
- Founded
- UFCS 1946
- AUTL 2014
- Country
- UFCS United States
- AUTL United Kingdom
- Employees
- UFCS N/A
- AUTL N/A
- Industry
- UFCS Property-Casualty Insurers
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UFCS Finance
- AUTL Health Care
- Exchange
- UFCS Nasdaq
- AUTL Nasdaq
- Market Cap
- UFCS 666.1M
- AUTL 625.4M
- IPO Year
- UFCS N/A
- AUTL 2018
- Fundamental
- Price
- UFCS $28.16
- AUTL $2.41
- Analyst Decision
- UFCS Buy
- AUTL Strong Buy
- Analyst Count
- UFCS 2
- AUTL 5
- Target Price
- UFCS $30.00
- AUTL $9.32
- AVG Volume (30 Days)
- UFCS 124.5K
- AUTL 2.1M
- Earning Date
- UFCS 08-05-2025
- AUTL 08-07-2025
- Dividend Yield
- UFCS 2.27%
- AUTL N/A
- EPS Growth
- UFCS N/A
- AUTL N/A
- EPS
- UFCS 2.54
- AUTL N/A
- Revenue
- UFCS $1,288,423,000.00
- AUTL $9,011,000.00
- Revenue This Year
- UFCS $11.31
- AUTL $461.76
- Revenue Next Year
- UFCS $10.61
- AUTL $112.66
- P/E Ratio
- UFCS $11.09
- AUTL N/A
- Revenue Growth
- UFCS 14.59
- AUTL N/A
- 52 Week Low
- UFCS $18.04
- AUTL $1.11
- 52 Week High
- UFCS $31.70
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- UFCS 48.57
- AUTL 70.63
- Support Level
- UFCS $27.31
- AUTL $2.20
- Resistance Level
- UFCS $28.95
- AUTL $2.44
- Average True Range (ATR)
- UFCS 0.68
- AUTL 0.12
- MACD
- UFCS -0.06
- AUTL -0.01
- Stochastic Oscillator
- UFCS 45.21
- AUTL 84.95
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.